Dr Reddy’s denied approval for Phase 3 trials of Sputnik Light vaccine


New Delhi [India], July 1 (ANI): The central government’s Subject Expert Committee (SEC) has denied permission to Dr Reddy’s Laboratories for conducting Phase 3 trials of Russia’s COVID-19 vaccine Sputnik Light in India.

“The SEC has denied permission to Dr Reddy’s to conduct phase-3 trials on the Russian vaccine Sputnik Light in India,” sources told ANI here.

After launching Sputnik V, Russia had introduced a new single-dose vaccine called Sputnik Light in May.

Sputnik Light has also been developed by the Russian Ministry of Health, the Gamaleya National Research Centre of Epidemiology Microbiology the Russian Direct Investment Fund (RDIF).

The RDIF had earlier said that the Russian Sputnik Light coronavirus vaccine demonstrates 78.6 per cent to 83.7 per cent efficacy among the elderly, according to real-world data collected by the Ministry of Health of the Buenos Aires province (Argentina).

According to the data from over 186,000 people aged 60-79, more than 40,000 of whom received a shot of Sputnik Light (first dose of Sputnik V) as part of the mass-scale civil vaccination program, the infection rate between 21st 40th day from the date of receiving the first dose was only 0.446 per cent.

At the same time, the infection rate among the non-vaccinated adult population was 2.74 per cent for a comparable period, according to an official release.

The safety, efficacy, lack of negative long-term effects of adenoviral vaccines have been proven by more than 250 clinical studies over two decades.

(Only the headline picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information commentary on developments that are of interest to you have wider political economic implications for the country the world. Your encouragement constant feedback on how to improve our offering have only made our resolve commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed updated with credible news, authoritative views incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better more relevant content. We believe in free, fair credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism subscribe to Business Standard.

Digital Editor

Source link